What Percentage of Lymph Node Biopsies Are Cancer?

Roughly 10 to 50 percent of lymph node biopsies reveal cancer, depending heavily on why the biopsy was performed in the first place. A diagnostic biopsy ordered because a node looks worrisome on imaging and has been growing for weeks carries a far higher cancer rate than a sentinel node biopsy done as a precautionary staging step during cancer surgery. The wide range reflects the fact that “lymph node biopsy” is not one procedure done for one reason but several different techniques performed across very different clinical scenarios.

Why the Number Varies So Much

The single biggest factor driving whether a lymph node biopsy turns up cancer is the level of clinical suspicion that prompted it. When a doctor removes a persistently enlarged node because it looks abnormal on ultrasound, has unusual texture, or has been growing for weeks without an obvious infectious cause, the pre-test probability of malignancy is already high. A twelve-year review at one surgical center found that about half of diagnostic excisional biopsies came back malignant.¹ By contrast, when a sentinel node is sampled during melanoma surgery, the positivity rate sits closer to 15 to 20 percent, because the procedure is designed to catch microscopic spread that might or might not be there.² And when an odd-looking node is spotted incidentally on a routine breast ultrasound in a woman with no cancer history, the malignancy rate can drop below two percent.³

So quoting a single percentage without context is misleading. The real question is which clinical scenario applies to you.

Diagnostic Excisional Biopsies Have the Highest Cancer Rates

When a surgeon removes an entire lymph node specifically to figure out what is wrong with it, the malignancy rate tends to be at the high end of the range. The single-center study mentioned above found cancer in about 49 percent of these cases, with lymphoma accounting for roughly a third of all patients and metastatic disease from other cancers making up the rest.¹ An older but larger statistical review reported that about 40 percent of biopsied nodes overall were malignant, splitting into roughly 28 percent carcinoma and 12 percent lymphoma, with the remaining 60 percent benign.⁴

Those numbers can sound alarming, but keep in mind the selection effect: these biopsies were not done on random people walking down the street. They were done on patients whose nodes had already passed through clinical and imaging evaluation and still looked suspicious enough to warrant tissue sampling. A node that shrinks on its own or responds to antibiotics rarely ends up being biopsied at all.

Where the Node Is Located Matters

The body site of the node shifts the odds. The same large statistical review found differences by anatomical region: peripheral nodes (neck, armpit, groin) had a malignancy rate of about 44 percent, with lymphoma making up a substantial share. Abdominal nodes showed a malignancy rate of about 37 percent, while intrathoracic (chest) nodes were the least likely to be cancerous at about 27 percent.⁴ Chest nodes, in particular, are often inflamed from inhaled particles, infections, or conditions like sarcoidosis rather than from cancer spread.

In the context of lung cancer staging, this distinction is critical. One study looked at 100 lymph node stations that lit up on PET-CT scans in patients with non-small cell lung cancer. Only 14 turned out to contain metastatic tumor. The rest were benign: 40 were anthracotic (discolored from inhaled dust or carbon), 39 were reactive, and several were granulomatous.⁵ That 14 percent malignancy rate among PET-positive nodes is a good reminder that “hot on a scan” does not mean “definitely cancer.”

Sentinel Lymph Node Biopsies in Cancer Staging

A sentinel lymph node biopsy is a different animal from a diagnostic biopsy. Instead of investigating a suspicious node, the surgeon is proactively checking the first node(s) that drain a known tumor site to see whether cancer has started spreading. This is standard practice in melanoma and breast cancer management.

In melanoma, a large analysis of nearly 49,000 patients found that about 16.5 percent had positive sentinel nodes.⁶ Separate studies of Australian and U.S. melanoma patients confirmed that roughly 15 to 21 percent of sentinel node biopsies come back positive.² That means four out of five melanoma patients who undergo the procedure learn their nodes are clear, which is reassuring but also raises questions about whether the procedure is always necessary.

In breast cancer, the picture is similar. One study evaluating preoperative prediction of axillary lymph node involvement found that about a quarter of patients turned out to have positive nodes on final pathology.⁷ Even when all four imaging modalities came back negative, 14 percent of patients still had cancer in their nodes at surgery, underscoring why tissue sampling remains the gold standard for staging.

What a “Benign” Result Actually Means

When a lymph node biopsy does not show cancer, the result is not always a simple “everything is fine.” The benign diagnoses cover a wide spectrum, some of which require their own treatment. In a study from a resource-limited setting, tuberculosis accounted for nearly half of all excisional biopsy results, dwarfing cancer as the most common finding.⁸ In a chest diseases hospital reviewing granulomatous inflammation specifically, sarcoidosis accounted for about 63 percent of cases and tuberculosis for about 22 percent, while a sarcoid reaction triggered by an underlying malignancy explained roughly 6 percent.⁹

Reactive lymphadenitis, the most common benign diagnosis in many settings, simply means the node was doing its job and responding to infection or inflammation. It requires no treatment and resolves on its own. But distinguishing reactive change from early lymphoma on a needle sample is sometimes difficult. Granulomatous diseases like sarcoidosis and tuberculosis can mimic each other histologically; a scoring tool combining factors such as weight loss, the presence of necrosis within granulomas, and certain blood markers could discriminate between the two with moderate accuracy.¹⁰

Children Are Different

Swollen lymph nodes are extremely common in children, and the overwhelming majority are reactive. When a pediatric oncology clinic evaluated children referred for lymphadenopathy, about 16 percent eventually underwent biopsy. Among those biopsied, 19 percent had cancer, but looking at the entire referred group, only 3 percent ultimately had a malignancy.¹¹ The most common malignancy in biopsied children was Hodgkin’s disease. Most of the other biopsied nodes turned out to be reactive or showed benign conditions like lymphangioma or ruptured epidermal cysts. This is worth knowing if you are a parent worried about a child’s swollen neck node: the vast majority of the time, it is a normal immune response to a recent infection.

Incidental Findings on Imaging

With the widespread use of ultrasound, CT, and MRI, radiologists frequently spot nodes that look mildly abnormal in patients being scanned for other reasons. These incidentally discovered suspicious nodes have much lower cancer rates than nodes that prompted the visit in the first place.

Among women who had abnormal-appearing axillary nodes found on breast screening or low-suspicion breast ultrasound and no cancer history, only about 1 percent turned out to have a malignancy.³ A separate study of women without a history of cancer who had incidentally detected, nonpalpable, suspicious regional lymph nodes on an otherwise normal breast ultrasound found no malignancies at biopsy or over several years of follow-up, leading the researchers to suggest that sampling these nodes could be safely avoided.¹²

In cervical lymph node surgery done for known conditions like thyroid cancer or other head and neck disease, about 2 percent of patients had an unanticipated neoplasm hiding in a node that nobody was worried about. The most common surprise findings were low-grade lymphomas and incidental metastatic papillary thyroid carcinoma.¹³

How Imaging Helps Predict the Result Before Biopsy

Doctors increasingly rely on ultrasound features to estimate whether a node is likely benign or malignant before deciding to biopsy. Features that independently predict malignancy include size over 1 centimeter, mixed internal echoes, the presence of necrosis inside the node, and the absence of a normal fatty center (the so-called hilar structure). One study found that every malignant node in its cohort had at least one of these features.¹⁴ However, no single ultrasound feature is reliable enough on its own. A systematic review of ultrasound characteristics during endobronchial procedures found that combining multiple features predicted malignancy more accurately than relying on any individual one.¹⁵

PET-CT scans, which detect areas of high metabolic activity, add another layer of information but come with a known weakness: inflammation lights up on PET scans just as cancer does. Inflammatory changes in nodes frequently produce false-positive results, which is why guidelines generally require biopsy confirmation of any PET-positive node before changing a treatment plan.¹⁶ The overlap in metabolic activity between benign and malignant nodes can be substantial, with benign nodes sometimes reaching high SUV values that mimic cancer.¹⁷

Biopsy Technique Affects What You Learn

Not all lymph node biopsies are equal in their ability to deliver a clear answer. The three main options are fine-needle aspiration (FNA), core needle biopsy (CNB), and excisional biopsy, in order of increasing invasiveness and diagnostic power.

A meta-analysis comparing FNA and core needle biopsy for suspicious cervical lymph nodes found that core biopsy was significantly more sensitive: it detected malignancy about 94 percent of the time versus 72 percent for FNA, while both had high specificity.¹⁸ Core biopsy was also reported to provide a diagnostic sample over twice as often as FNA in lymph nodes considered high-risk on ultrasound.¹⁹

A randomized trial comparing ultrasound-guided core needle biopsy to traditional open surgical biopsy for suspected lymphoma found the core needle approach was actually more sensitive (about 99 percent versus 89 percent), while also being faster, less expensive, and causing fewer complications.²⁰ That said, excisional biopsy still has a role when the full architecture of the node is needed to make a precise lymphoma subtype diagnosis, since treatment varies by subtype.

For axillary staging in breast cancer specifically, the gap between techniques narrowed, with FNA sensitivity at about 75 percent and core needle at about 82 percent in one head-to-head comparison.²¹ The practical takeaway: if a needle biopsy comes back negative but the node still looks suspicious, a repeat biopsy with a different technique or a full excision may be warranted. A negative FNA is less reassuring than a negative core biopsy.

Does Examining More Nodes Change the Cancer Rate?

In colon cancer surgery, pathologists examine the lymph nodes removed alongside the tumor to check for spread. Over the past few decades, surgical standards have shifted toward removing and examining more nodes. A study spanning 20 years of U.S. colon cancer data found that the proportion of patients who had 12 or more nodes evaluated rose from about 35 percent in the late 1980s to roughly 74 percent by the late 2000s. Yet the proportion of patients found to be node-positive barely budged, hovering around 40 to 42 percent throughout.²²

What did change was survival. Patients who had more nodes examined had significantly lower five-year mortality, even though they were only slightly more likely to be classified as node-positive. The benefit appears to come from more accurate staging and better-tailored treatment decisions rather than from finding more cancer per se. In other words, the percentage of positive biopsies stayed the same, but the clinical value of doing a thorough job went up.

The Cost Question Around Low-Yield Biopsies

When sentinel lymph node biopsy positivity rates sit in the range of 15 to 20 percent, that means four of every five procedures find nothing malignant. For high-risk cutaneous squamous cell carcinoma, where sentinel node metastasis rates can be even lower, researchers have raised concerns that performing sentinel biopsies on all patients may be unnecessary and costly relative to the diagnostic yield.²³ One approach to improve cost-effectiveness is pre-screening with ultrasound: a cost-effectiveness analysis of melanoma patients found that adding ultrasound before sentinel node biopsy was the dominant strategy, producing better staging at lower overall cost than performing sentinel biopsy alone.²⁴

The tension is real: miss a positive node and the patient may not get the adjuvant therapy they need; biopsy every mildly suspicious node and you subject many people to a procedure that will not change their treatment. The trend in oncology is toward better pre-biopsy risk stratification, using combinations of imaging features, tumor characteristics, and clinical scores, so that biopsies are directed toward patients most likely to benefit.

Liquid Biopsy as a Complement

A newer and less invasive way to look for signs of cancer spread is liquid biopsy, which analyzes fragments of tumor DNA circulating in the blood. This technology is still finding its clinical footing, but early data suggest it could eventually help clarify ambiguous lymph node findings. In biliary tract cancers, for instance, the presence of lymph node metastases was one of several factors that predicted whether a liquid biopsy would detect actionable tumor mutations, suggesting that the two approaches capture overlapping information about disease spread.²⁵ Liquid biopsy is unlikely to replace tissue biopsy for lymph node diagnosis anytime soon, since tissue remains necessary for precise tumor typing and grading. But it may eventually reduce the number of ambiguous cases that require invasive sampling.